Summary Summary Short summary of a recent publication, written by scientific experts. Published: May 01, 2019

The role of DNAJB6 and glycogen synthase kinase-β in limb-girdle muscular dystrophy 1D

Takeaway

  • Dominant mutations in DNAJB6 inhibit myogenic signaling via enhanced glycogen synthase kinase-β (GSK3β) activity in limb-girdle muscular dystrophy 1D (LGMD1D).

Why this matters

    Inhibition of GSK3β with lithium chloride (LiCl) may be of therapeutic interest in the treatment of LGMD1D.